Combination of two immunotherapies shows activity in non-small cell lung cancer patients

November 14, 2018

Dublin, Ireland: A combination of two drugs, which prompt the body's immune system to identify and kill cancer cells, is a safe treatment for patients with advanced non-small cell lung cancer and has shown some signs of efficacy.

Results from a phase I/II clinical trial in 25 patients, presented at the 30th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, today (Thursday), identified the maximum tolerated doses at which NIR178 (PBF-509) and spartalizumab (PDR001) could be given to patients whose disease had either failed to respond or stopped responding to previous treatments. The disease shrank or disappeared in two patients and it remained stable, without progressing, in 14 patients.

Tumours are surrounded by blood vessels, normal cells and molecules that make up the tumour's microenvironment. In order to grow and spread, tumours recruit various molecules to suppress the body's immune system, which would otherwise recognise and kill cancer cells. Adenosine is one molecule that suppresses the immune system in the tumour microenvironment, but previous research has shown that its activity can be blocked by NIR178. Spartalizumab is a monoclonal antibody that blocks PD-1, a molecule that acts as a checkpoint to regulate the immune response.

Researchers, led by Professor Alberto Chiappori (MD) from the Moffitt Cancer Center, Tampa, USA, wanted to investigate whether the combination of these two immunotherapies might be more effective against non-small cell lung cancer than either drug on its own.

Between August 2016 and January 2018, the study enrolled 25 patients with advanced non-small cell lung cancer who had been treated already with at least one therapy and either failed to respond or relapsed. "Most of these patients were heavily pre-treated with chemotherapy, radiation and immunotherapy," said Prof Chiappori. However, they were still fairly fit, being either fully active, with everyday life unaffected by their disease, or restricted in physically strenuous activity, but able to carry out work of a light or sedentary nature (ECOG performance status 0-1). The average age was 64, 60% were men, and 44% had received prior anti-PD-1 or PD-L1 therapy.

Spartalizumab was administered intravenously at a fixed dose of 400 mg once every four weeks. NIR178 was given orally in pill form, twice daily at escalating doses of 160 mg, 240 mg and 320 mg.

By August 2018, 23 (92%) of the patients had discontinued the treatment due to disease progression (13), death for reasons unrelated to the treatment (4), adverse side effects of the treatment (4), and withdrawal of consent to continue in the trial (2). Two patients remained on the treatment.

In 14 other patients who had not received prior anti-PD-1/L1 therapies, one (7%) experienced a complete response to the treatment, with the cancer disappearing, a second (7%) had a partial response, with the cancer shrinking, and six (43%) had stable disease. In 11 patients who had been pre-treated with anti-PD-1/L1 therapies and experienced a disease progression, eight (73%) had stable disease.

The most frequent treatment-related side effects were nausea, liver problems, fatigue and an increase in the pancreatic enzyme, lipase. Two patients suffered from severe but not life-threatening (grade 3) inflammation of lung tissues. There were no life-threatening (grade 4) treatment-related side effects.

The maximum tolerated dose was determined as 240 mg of NIR178 twice daily, and 400 mg of spartalizumab every four weeks.

"This was an early phase I/II trial of the combined treatment," said Prof Chiappori. "We believe that observing responses in these heavily pre-treated patients is always a positive sign that represents the potential anti-tumour activity of the regimen and gives a preliminary measure of the importance of continuing to investigate it in further, more definitive studies. The regimen is already being tested in phase II trials of several other solid tumours and non-small cell lung cancer. We are also working on further understanding the mechanism of action of the combination of the two drugs in the body."

Co-chair of the EORTC-NCI-AACR Symposium, Professor Antoni Ribas from the University of California Los Angeles, who was not involved in the research, commented: "Non-small cell lung cancer is one of the hardest cancers to treat successfully, particularly when it has spread to other parts of the body. Increasingly, we are seeing that drugs that encourage the immune system to attack the cancer may work better together than alone. The results from this early clinical trial suggest that further testing of the combination of NIR178 and spartalizumab is warranted in this type of lung cancer."
-end-
[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research].

ECCO-the European CanCer Organisation

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.